Infinity Pharmaceuticals has scuttled a plan to combine with MEI Pharma, whose shareholders rebuffed the merger over the weekend, the company announced Monday morning. The announcement comes days ...
A Massachusetts biotech is clearing out its C-suite in the wake of a failed merger agreement that had already cost 21 jobs. Infinity Pharmaceuticals Inc. (Nasdaq: INFI) CEO Adelene Perkins, chief ...
With the dearth of Big Pharma buyouts and against the backdrop of a tough market, one trend so far in 2023 has been biotech-to-biotech mergers. The latest example sees Infinity Pharmaceuticals ...
Infinity to Explore Strategic Alternatives to Maximize Value for Stockholders CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage ...
MEI Pharma may already have a merger lined up with Infinity Pharmaceuticals, but another suitor has emerged from the fray. MEI Pharma announced Tuesday evening it has received a proposal from ...
Infinity Pharmaceuticals (OTC:INFI) has reportedly filed for bankruptcy in the wake of a terminated merger deal with MEI Pharma. The biotech company filed for Chapter 11 bankruptcy protection in a ...
– Infinity Previously Announced Definitive Merger Agreement with MEI Pharma to Advance Three Promising Clinical Oncology Candidates – Research and development expenses for 2022 were $32.4 million, ...
Infinity Pharmaceuticals will be releasing earnings Q3 on November 14. Analysts predict Infinity Pharmaceuticals will release losses per share of $0.120. Go here to follow Infinity Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback